Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction

F. M. Curran, U. Bhalraam, M. Mohan, J. S. Singh, S. D. Anker, K. Dickstein, A. S. Doney, G. Filippatos, J. George, M. Metra, L. L. Ng, C. N. Palmer, N. J. Samani, D. J. van Veldhuisen, A. A. Voors, C. C. Lang, I. R. Mordi

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)

Abstract

Inflammation is thought to play a role in heart failure (HF) pathophysiology. Neutrophil-to-lymphocyte ratio (NLR) is a simple, routinely available measure of inflammation. Its relationship with other inflammatory biomarkers and its association with clinical outcomes in addition to other risk markers have not been comprehensively evaluated in HF patients.|We evaluated patients with worsening or new-onset HF from the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) study who had available NLR at baseline. The primary outcome was time to all-cause mortality or HF hospitalization. Outcomes were validated in a separate HF population.|1622 patients were evaluated (including 523 ventricular ejection fraction [LVEF] 
Original languageEnglish
Pages (from-to)3168-3179
Number of pages12
JournalESC Heart Failure
Volume8
Issue number4
DOIs
Publication statusPublished - 2021

Keywords

  • Heart Failure Humans Lymphocytes Neutrophils Prognosis Stroke Volume Biomarkers Heart failure Inflammation Neutrophil-to-lymphocyte ratio Outcome

Fingerprint

Dive into the research topics of 'Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction'. Together they form a unique fingerprint.

Cite this